SCHEDULE: General Atlantic Discloses 3.2% Stake in Royalty Pharma

General Atlantic and its affiliated entities have disclosed a beneficial ownership of 3.2% in Royalty Pharma plc, holding over 14.2 million Class A ordinary shares.

Summary

• General Atlantic, L.P. and a group of 18 affiliated entities (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Royalty Pharma plc.
• The filing indicates that as of June 30, 2025, the Reporting Persons beneficially own an aggregate of 14,243,870 Class A ordinary shares of Royalty Pharma plc.
• This ownership represents approximately 3.2% of the total issued and outstanding Class A ordinary shares of Royalty Pharma plc.
• The 14,243,870 shares are primarily held indirectly by General Atlantic (RP) Collections, LLC, corresponding to an equal number of Class B interests of Royalty Pharma Holdings Ltd, which are convertible into Class A ordinary shares.
• The calculation of percentage ownership is based on an aggregate of 446,536,920 Class A ordinary shares outstanding, including 432,293,050 shares reported by Royalty Pharma plc as of August 1, 2025, and the 14,243,870 convertible Class B shares.
• The Reporting Persons share voting and dispositive power over the 14,243,870 shares.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant ownership by an investment firm in a publicly traded company within the pharmaceutical sector. It reflects General Atlantic's continued or adjusted investment position in Royalty Pharma plc, a company known for acquiring pharmaceutical royalties.

Related Party Transactions

• The filing details a complex group structure of 19 General Atlantic entities that are deemed to be acting as a group and beneficially own the shares. This structure involves various limited partnerships and LLCs, with control ultimately residing with the Partnership Committee of GASC MGP, LLC. This outlines the internal related-party relationships within the General Atlantic reporting group.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence market perception and trading activity.

Key Dates

Keywords

Royalty Pharma, General Atlantic, Beneficial Ownership, SEC Filing, Schedule 13G, Class A Shares, Investment, Pharmaceuticals, Biotech